Boehringer Ingelheim is discarding an inhaled gene therapy designed to treat cystic fibrosis (CF) after terminating a phase 1 ...

Compass Pathways has reported another phase 3 win for its psilocybin therapy in treatment-resistant depression, sending the ...

Sanofi and Teva had already shown in late 2024 that the anti-TL1A antibody, called duvakitug, improved outcomes in ulcerative ...

The FDA gave the go-ahead to Novocure for its tumor-treating electric fields device that targets advanced pancreatic cancer ...

Preclinical CRO RoukenBio has inked a partnership with Connecticut-based biologics discovery specialist AVS Bio that aims to leverage each others' strengths to avoid late-stage trial failures and ...

Japan-based cell therapy company Innovacell is planning to end a drought of biotech IPOs on the Tokyo stock exchange next week, the business’ CEO has confirmed. | Japan-based cell therapy company ...

Cyrano Therapeutics is savoring a phase 2 victory. With the Flavor study hitting its primary endpoint, the biotech is preparing to take its treatment for persistent smell loss into phase 3 in the ...

Gilead has secured another synthetic lethal therapy, handing over $80 million upfront for the global rights to a clinic-ready cancer drug from China’s Genhouse Bio. | Gilead has secured another ...

Just as a disciplined a soccer player might pass on a hopeful shot in favor of a better chance later on, the biopharma ...

After the FDA's surprise refusal to take up a review of Moderna's next-gen flu vaccine, the public disagreement between U.S.

Takeda’s real estate downsize will add to the region’s growing office sublease market. A January 2026 CBRE report on the ...

Ultragenyx Pharmaceutical's employees were already braced for changes as the biopharma considered how to rebound from a pair ...